ProKidney (PROK) Stock Forecast, Price Target & Predictions
PROK Stock Forecast
ProKidney stock forecast is as follows: an average price target of $4.67 (represents a 159.44% upside from PROK’s last price of $1.80) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
PROK Price Target
The average price target for ProKidney (PROK) is $4.67 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $3.00. This represents a potential 159.44% upside from PROK's last price of $1.80.
PROK Analyst Ratings
According to 7 Wall Street analysts, ProKidney's rating consensus is 'Buy'. The analyst rating breakdown for PROK stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ProKidney Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Jason Gerberry | Bank of America Securities | $3.00 | $2.40 | 25.00% | 66.67% |
| Sep 03, 2024 | Justin Zelin | BTIG | $5.00 | $2.40 | 108.33% | 177.78% |
| Jun 10, 2024 | Kelly Shi | Jefferies | $6.00 | $3.02 | 98.68% | 233.33% |
| May 28, 2024 | Justin Zelin | BTIG | $6.00 | $3.71 | 61.73% | 233.33% |
| Dec 21, 2022 | - | Jefferies | $15.00 | $7.30 | 105.48% | 733.33% |
The latest ProKidney stock forecast, released on Sep 04, 2024 by Jason Gerberry from Bank of America Securities, set a price target of $3.00, which represents a 25.00% increase from the stock price at the time of the forecast ($2.40), and a 66.67% increase from PROK last price ($1.80).
ProKidney Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $4.00 | $5.00 |
| Last Closing Price | $1.80 | $1.80 | $1.80 |
| Upside/Downside | -100.00% | 122.22% | 177.78% |
In the current month, the average price target of ProKidney stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProKidney's last price of $1.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Guggenheim | - | Buy | Initialise |
| Sep 03, 2024 | BTIG | Buy | Buy | Hold |
| Jun 10, 2024 | Jefferies | Buy | Buy | Hold |
| May 29, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| May 28, 2024 | BTIG | Buy | Buy | Hold |
| Dec 21, 2022 | Jefferies | - | Buy | Initialise |
| Oct 14, 2022 | Citigroup | - | Buy | Initialise |
| Sep 02, 2022 | Wells Fargo | - | Overweight | Initialise |
| Sep 02, 2022 | Evercore ISI | - | Outperform | Initialise |
ProKidney's last stock rating was published by Guggenheim on Sep 10, 2024. The company Initialise its PROK rating from "null" to "Buy".
ProKidney Financial Forecast
ProKidney Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | - |
| Surprise % | - | - | - | - |
ProKidney's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PROK's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ProKidney EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict PROK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ProKidney's previous annual EBITDA (undefined) of $NaN.
ProKidney Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| Net Income | - | - | - | - |
| Avg Forecast | $-22.71M | $-17.13M | $-16.10M | $-19.20M |
| High Forecast | $-22.71M | $-11.01M | $-16.10M | $-19.20M |
| Low Forecast | $-22.71M | $-23.25M | $-16.10M | $-19.20M |
| Surprise % | - | - | - | - |
ProKidney's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PROK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ProKidney SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
ProKidney's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PROK last annual SG&A of $NaN (undefined).
ProKidney EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | - |
| EPS | - | - | - | - |
| Avg Forecast | $-0.18 | $-0.14 | $-0.13 | $-0.25 |
| High Forecast | $-0.18 | $-0.09 | $-0.13 | $-0.25 |
| Low Forecast | $-0.18 | $-0.18 | $-0.13 | $-0.25 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, ProKidney's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PROK previous annual EPS of $NaN (undefined).
ProKidney Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.78 | $33.86 | 1802.25% | Buy |
| PMVP | PMV Pharmaceuticals | $1.59 | $18.00 | 1032.08% | Buy |
| LYEL | Lyell Immunopharma | $1.11 | $6.67 | 500.90% | Hold |
| BDTX | Black Diamond Therapeutics | $2.55 | $14.75 | 478.43% | Buy |
| RLAY | Relay Therapeutics | $4.80 | $19.40 | 304.17% | Buy |
| ARVN | Arvinas | $21.64 | $71.00 | 228.10% | Buy |
| PLRX | Pliant Therapeutics | $12.79 | $39.71 | 210.48% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| PROK | ProKidney | $1.80 | $4.67 | 159.44% | Buy |
| ERAS | Erasca | $2.79 | $6.50 | 132.97% | Buy |
| REPL | Replimune Group | $10.95 | $24.20 | 121.00% | Buy |
| IMCR | Immunocore | $32.56 | $70.75 | 117.29% | Buy |
| MRUS | Merus | $43.49 | $77.13 | 77.35% | Buy |
| KURA | Kura Oncology | $15.96 | $26.00 | 62.91% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| PCVX | Vaxcyte | $87.08 | $124.00 | 42.40% | Buy |
| THRD | Third Harmonic Bio | $12.46 | $16.15 | 29.61% | Buy |
| PTGX | Protagonist Therapeutics | $38.65 | $50.00 | 29.37% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
| ACLX | Arcellx | $87.59 | $83.00 | -5.24% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |